Entrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Ventures V. L.P. 5Am Sells 18,578 Shares

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) major shareholder Ventures V. L.P. 5Am sold 18,578 shares of the business's stock in a transaction that occurred on Monday, June 30th. The stock was sold at an average price of $6.81, for a total value of $126,516.18. Following the transaction, the insider directly owned 3,201,709 shares in the company, valued at $21,803,638.29. This trade represents a 0.58% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.

Entrada Therapeutics Price Performance

TRDA stock traded up $0.39 during midday trading on Tuesday, reaching $7.11. 205,752 shares of the company were exchanged, compared to its average volume of 134,114. Entrada Therapeutics, Inc. has a one year low of $6.53 and a one year high of $21.79. The firm has a market capitalization of $269.82 million, a price-to-earnings ratio of 8.30 and a beta of -0.11. The business has a 50-day moving average price of $8.01 and a two-hundred day moving average price of $10.88.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.78) by $0.36. Entrada Therapeutics had a net margin of 14.39% and a return on equity of 5.84%. The business had revenue of $8.75 million during the quarter, compared to the consensus estimate of $10.98 million. As a group, analysts anticipate that Entrada Therapeutics, Inc. will post 1.12 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

TRDA has been the topic of a number of recent analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $20.00 price target on shares of Entrada Therapeutics in a research report on Tuesday, May 20th. Wall Street Zen upgraded shares of Entrada Therapeutics from a "sell" rating to a "hold" rating in a research note on Friday. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $25.67.

Hedge Funds Weigh In On Entrada Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. KLP Kapitalforvaltning AS bought a new stake in Entrada Therapeutics in the 4th quarter valued at $36,000. BNP Paribas Financial Markets bought a new stake in shares of Entrada Therapeutics in the fourth quarter valued at about $57,000. Virtus ETF Advisers LLC acquired a new position in shares of Entrada Therapeutics in the fourth quarter valued at about $68,000. AlphaQuest LLC bought a new position in Entrada Therapeutics during the fourth quarter worth about $70,000. Finally, Russell Investments Group Ltd. raised its stake in Entrada Therapeutics by 53,455.6% in the 4th quarter. Russell Investments Group Ltd. now owns 4,820 shares of the company's stock worth $83,000 after purchasing an additional 4,811 shares in the last quarter. Institutional investors and hedge funds own 86.39% of the company's stock.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.